The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 23, 2018

Filed:

Sep. 30, 2016
Applicant:

Icahn School of Medicine AT Mount Sinai, New York, NY (US);

Inventors:

Roger Joseph Hajjar, Tenafly, NJ (US);

Chang Won Kho, New York, NY (US);

Ah Young Lee, New York, NY (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/6883 (2018.01); C12N 15/861 (2006.01); A61K 38/50 (2006.01); A61K 31/7088 (2006.01); A61K 38/17 (2006.01); G01N 33/573 (2006.01); A61K 48/00 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
A61K 38/50 (2013.01); A61K 31/7088 (2013.01); A61K 38/1709 (2013.01); A61K 48/0066 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); C12Q 1/6883 (2013.01); C12Y 305/00 (2013.01); G01N 33/573 (2013.01); C12N 2750/14143 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/914 (2013.01); G01N 2440/36 (2013.01); G01N 2800/325 (2013.01);
Abstract

Methods for treating cardiovascular disease, and in particular heart failure, are provided comprising administering a therapeutically effective amount of a modulator of SERCA2a post-translation modification such as SUMOylation or acetylation. Also provided are methods of treating cardiovascular disease by inhibiting SERCA2a degradation. Further provided are methods of diagnosing a propensity to develop heart failure comprising determining if a SERCA2a mutant is present or determining the level of expression of SUMO1 in cardiomyocytes. The disclosure also provides methods of screening for therapeutics that modulate the post-translational modification of SERCA2a, such as by modulating post-translational SUMOylation and/or acetylation.


Find Patent Forward Citations

Loading…